National Early Inflammatory Autoimmune Diseases Audit

Scope as published

The contract is expected to initially be delivered for NHS-funded care in England and Wales, and publicly funded care in Jersey for a period of three years, at a maximum total budget of up to £933,979.20 GBP including VAT and £778,316.00 GBP excluding VAT. Bids exceeding this limit will be rejected. There is potential to extend the contract for up to two additional years as well as the option to include other Devolved Nations and/or Crown Dependencies, aspirational measures and discretionary inflationary uplifts (all of which will be defined in the service specification). The maximum budget ‘core’ value of £933,979.20 GBP including VAT and £778,316.00 GBP excluding VAT, excludes the potential two-year extension and aspirational intent as included in section 14.4 of Annex A - Service Specification The contract may be extended for up to 24 months at a pro rata value of the core three- year funding, estimated at up to £518,877 excluding VAT. This proposed extension value may also include pro rata funding of any additional aspirational measures invoked in the first three years of the contract. For example: If an aspirational annual requirement costing £500,000 per year is invoked in year three, then the extension funding (if the aspirational measure is continued) will be the above figures plus the additional £500,000 per year. Further to this funding, the specification contains a list of aspirational measures which will be expected to be modified into the contract should the need and funding become available. The aspirational intent value, including the potential two- year extension and core 3 year value means an overall ceiling value for this contract of up to £6,417,788 excluding VAT and £7,701,346 including VAT. This aspirational intent has the potential to be invoked fully, partially, or not at all, and the Authority cannot guarantee that the successful supplier will be required to do any of the aspirational measures listed in section 14.4 of Annex A - Service Specification The role of a national clinical audit is to stimulate healthcare quality improvement through the provision of high-quality information on the organisation, delivery and outcomes of healthcare, together with tools and support to enable healthcare providers and other audiences to make best use of this information. Outcomes are benchmarked against available national guidance and standards e.g. quality standards from the National Institute for Health and Care Excellence (NICE), and those from other established professional and patient sources. Successful national audits are those where the individuals who are engaging with and using the audit results are also in a position to improve the system, and where there is a shared understanding of what good care looks like. National clinical audits are expected to: a.Develop a robust, high-quality audit designed around key quality metrics likely to best support local and national healthcare quality improvement. b.Detect, describe and help reduce unwarranted clinical variation by systematically benchmarking performance, identifying outliers, and supporting services to understand variation in outcomes, processes and experience. c.Achieve, articulate and maintain close alignment with relevant NICE national guidance and quality standards throughout the audit, as appropriate. d.Enable healthcare quality improvement through the provision of timely, high-quality data that compares providers of healthcare, and comprises an integrated mixture of named Trust or Health board, Integrated Care System (ICS), commissioner, multidisciplinary team (MDT), possibly consultant or clinical team level and other levels of reporting. e.Engage patients, carers and the public in a meaningful way, achieving a strong patient voice which informs and contributes to the design, functioning, outputs and direction of the audit. f.Consider the value and feasibility of linking data at an individual patient level to other relevant national datasets eithe…

Classifications